Pharming Group NV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.8
- Today's High:
- $12.92
- Open Price:
- $12.91
- 52W Low:
- $8.65
- 52W High:
- $17.81
- Prev. Close:
- $12.45
- Volume:
- 1081
Company Statistics
- Market Cap.:
- $845.04 million
- Book Value:
- 3.04
- Revenue TTM:
- $206.30 million
- Operating Margin TTM:
- -13.1%
- Gross Profit TTM:
- $188.06 million
- Profit Margin:
- -7.96%
- Return on Assets TTM:
- -4.1%
- Return on Equity TTM:
- -8.21%
Company Profile
Pharming Group NV had its IPO on 2020-12-23 under the ticker symbol PHAR.
The company operates in the Healthcare sector and Biotechnology industry. Pharming Group NV has a staff strength of 332 employees.
Stock update
Shares of Pharming Group NV opened at $12.91 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.8 - $12.92, and closed at $12.8.
This is a +2.81% increase from the previous day's closing price.
A total volume of 1,081 shares were traded at the close of the day’s session.
In the last one week, shares of Pharming Group NV have increased by +8.21%.
Pharming Group NV's Key Ratios
Pharming Group NV has a market cap of $845.04 million, indicating a price to book ratio of 4.0626 and a price to sales ratio of 3.6344.
In the last 12-months Pharming Group NV’s revenue was $206.30 million with a gross profit of $188.06 million and an EBITDA of $-21412000. The EBITDA ratio measures Pharming Group NV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pharming Group NV’s operating margin was -13.1% while its return on assets stood at -4.1% with a return of equity of -8.21%.
In Q2, Pharming Group NV’s quarterly earnings growth was a negative -92.8% while revenue growth was a positive 9.5%.
Pharming Group NV’s PE and PEG Ratio
- Forward PE
- 156.25
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.23 per share while it has a forward price to earnings multiple of 156.25 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pharming Group NV’s profitability.
Pharming Group NV stock is trading at a EV to sales ratio of 3.5392 and a EV to EBITDA ratio of 12.1487. Its price to sales ratio in the trailing 12-months stood at 3.6344.
Pharming Group NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $429.81 million
- Total Liabilities
- $64.95 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $771000
- Dividend Payout Ratio
- 0%
Pharming Group NV ended 2024 with $429.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $429.81 million while shareholder equity stood at $200.37 million.
Pharming Group NV ended 2024 with $0 in deferred long-term liabilities, $64.95 million in other current liabilities, 7540000.00 in common stock, $-265494000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $192.37 million and cash and short-term investments were $192.37 million. The company’s total short-term debt was $5,653,000 while long-term debt stood at $134.18 million.
Pharming Group NV’s total current assets stands at $278.57 million while long-term investments were $9.65 million and short-term investments were $0. Its net receivables were $33.16 million compared to accounts payable of $59.30 million and inventory worth $53.04 million.
In 2024, Pharming Group NV's operating cash flow was $0 while its capital expenditure stood at $771000.
Comparatively, Pharming Group NV paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.8
- 52-Week High
- $17.81
- 52-Week Low
- $8.65
- Analyst Target Price
- $
Pharming Group NV stock is currently trading at $12.8 per share. It touched a 52-week high of $17.81 and a 52-week low of $17.81. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $12.13 and 200-day moving average was $12.11 The short ratio stood at 1.45 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 4.3% are held by institutions.
Frequently Asked Questions About Pharming Group NV
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.